Nebulized Bacteriophage Therapy in Cystic Fibrosis Patients With Chronic Pseudomonas Aeruginosa Pulmonary Infection
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT05010577 |
Recruitment Status :
Active, not recruiting
First Posted : August 18, 2021
Last Update Posted : October 18, 2023
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Chronic Pseudomonas Aeruginosa Infection Cystic Fibrosis | Drug: BX004-A Drug: Placebo | Phase 1 Phase 2 |
Study Type : | Interventional (Clinical Trial) |
Estimated Enrollment : | 32 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor) |
Primary Purpose: | Treatment |
Official Title: | A Phase 1b/2a, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate Nebulized Bacteriophage Treatment in Outpatient Adult Cystic Fibrosis (CF) Subjects With Chronic Pseudomonas Aeruginosa (PsA) Pulmonary Infection |
Actual Study Start Date : | June 21, 2022 |
Estimated Primary Completion Date : | October 2023 |
Estimated Study Completion Date : | March 2024 |
Arm | Intervention/treatment |
---|---|
Experimental: BX004-A
Participants will be randomized to receive standard dose of nebulized bacteriophage
|
Drug: BX004-A
Combination of nebulized bacteriophages targeting Pseudomonas aeruginosa
Other Name: Bacteriophage |
Placebo Comparator: Placebo
Participants will be randomized to receive nebulized placebo
|
Drug: Placebo
Nebulized placebo
Other Name: Vehicle buffer |
- Safety and tolerability [ Time Frame: 6 months ]Incidence of treatment emergent adverse events following single and multiple doses of BX004-A administered by inhalation
- PsA burden in sputum at various timepoints [ Time Frame: 1 month ]Change in PsA colony-forming units (CFU) per gram of sputum
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Key Inclusion Criteria:
- Cystic fibrosis patients with chronic Pseudomonas aeruginosa pulmonary infection receiving standard of care CF medications
- Age ≥ 18 years
- FEV1 ≥ 40% predicted
- Clinically stable lung disease
- Willing and able to provide adequate sputum samples, using any method (spontaneously expectorated, induced, from home or clinic) at designated study visits.
Key Exclusion Criteria:
- Known hypersensitivity to bacteriophages or excipients in the formulation.
- Receipt of prior bacteriophage therapy within the 6 months prior to Screening
- Recovery of Burkholderia species from respiratory tract within 1 year prior to screening
- Currently receiving treatment for allergic bronchopulmonary aspergillosis
- Currently receiving treatment for active infection with non-tuberculous mycobacteria
- History of severe neutropenia
- History of lung transplant
- History of solid organ transplant
- Acquired or primary immunodeficiency syndrome
- Initiation or change in CF modulator therapy less than 3 months prior to screening
- Pregnant or breastfeeding female
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05010577
Study Director: | Urania Rappo, MD | BiomX, Inc. |
Responsible Party: | BiomX, Inc. |
ClinicalTrials.gov Identifier: | NCT05010577 |
Other Study ID Numbers: |
BMX-04-001 |
First Posted: | August 18, 2021 Key Record Dates |
Last Update Posted: | October 18, 2023 |
Last Verified: | October 2023 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | No |
Studies a U.S. FDA-regulated Drug Product: | Yes |
Studies a U.S. FDA-regulated Device Product: | No |
Infections Communicable Diseases Pseudomonas Infections Cystic Fibrosis Fibrosis Disease Attributes Pathologic Processes Pancreatic Diseases |
Digestive System Diseases Lung Diseases Respiratory Tract Diseases Genetic Diseases, Inborn Infant, Newborn, Diseases Gram-Negative Bacterial Infections Bacterial Infections Bacterial Infections and Mycoses |